# More than 10 loss-making biotechnology companies have filed for Hong Kong stock exchange listings.

*biotech · news · 2026-03-16 · South China Morning Post*

## Key points

- Over 10 unprofitable biotech firms have filed for Hong Kong listings in 2024.
- Hong Kong's healthcare and biotech equity capital market activity hit US$15.6 billion in 2023.
- Diagens Biotechnology's AI platform reduces genetic analysis from 30 days to 4-7 days.
- Diagens expects Chinese regulatory approval in Q1 and plans to seek FDA approval in April.

**Companies:** Hangzhou Diagens Biotechnology, Exegenesis Bio
**Countries:** China

[Read the full story on South China Morning Post](https://www.scmp.com/business/banking-finance/article/3346710/hong-kong-attracts-wave-biotech-ipo-filings-amid-ai-drug-boom)

---

Canonical: https://newsio.io/n/1c32cc94-93cd-4c98-917e-7a28c979f18b/more-than-10-loss-making-biotechnology-companies-have-filed-for-hong-kong-stock
Summarized by Newsio from South China Morning Post. https://newsio.io/how-it-works